Digestive Diseases and Sciences

, Volume 58, Issue 2, pp 344–348 | Cite as

Overlap Syndromes of Autoimmune Hepatitis: An Open Question

  • Marilena DurazzoEmail author
  • Alberto Premoli
  • Elena Paschetta
  • Paola Belci
  • Maurizio Spandre
  • Simona Bo


The headword “overlap syndromes” of liver diseases includes the coexistence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. These syndromes often represent a diagnostic and therapeutic challenge for hepatologists; it remains unclear whether these overlap syndromes form distinct entities or they are only variants of the major autoimmune liver diseases. The most frequent reported association occurs between autoimmune hepatitis and primary biliary cirrhosis, whereas the overlap between autoimmune hepatitis and primary sclerosing cholangitis is less frequent, typically at young age and often attendant with an inflammatory bowel disease. The choice therapy is based on ursodeoxycholic acid and immunosuppressive drugs, used at the same time or consecutively, according to the course of disease. The diagnostic scores for autoimmune hepatitis can help for diagnosis, even though their definitive soundness is lacking.


Overlap syndrome Autoimmune hepatitis Primary biliary cirrhosis Primary sclerosing cholangitis 


Conflict of interest



  1. 1.
    Durazzo M, Premoli A, Fagoonee S, Pellicano R. Overlap syndrome of autoimmune hepatitis: what is known so far. Dig Dis Sci. 2003;48:423–430.PubMedCrossRefGoogle Scholar
  2. 2.
    Burak KW, Urbanski SJ, Swain MG. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci. 2001;46:2043–2047.PubMedCrossRefGoogle Scholar
  3. 3.
    Kingham JG, Abbasi A. Co-existence of primary biliary cirrhosis and primary sclerosing cholangitis: a rare overlap syndrome put in perspective. Eur J Gastroenterol Hepatol. 2005;17:1077–1080.PubMedCrossRefGoogle Scholar
  4. 4.
    Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994;19:841–848.PubMedCrossRefGoogle Scholar
  5. 5.
    Muratori P, Muratori L, Stroffolini T, et al. Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clin Exp Immunol. 2003;131:118–121.PubMedCrossRefGoogle Scholar
  6. 6.
    Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol. 1999;31:210–216.PubMedCrossRefGoogle Scholar
  7. 7.
    Beuers U, Rust C. Overlap syndromes. Semin Liver Dis. 2005;25:311–320.PubMedCrossRefGoogle Scholar
  8. 8.
    Poupon R, Chazouilleres O, Corpechot C, Chrétien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296–301.PubMedCrossRefGoogle Scholar
  10. 10.
    Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–385.PubMedCrossRefGoogle Scholar
  11. 11.
    Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360–365.PubMedCrossRefGoogle Scholar
  12. 12.
    Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996;125:588–598.PubMedGoogle Scholar
  13. 13.
    Bonder A, Retana A, Winston DM, Leung J, Kaplan MM. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2011;9:609–612.PubMedCrossRefGoogle Scholar
  14. 14.
    Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999;29:1078–1084.PubMedCrossRefGoogle Scholar
  15. 15.
    Heurguè A, Vitry F, Diebold MD, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007;31:17–25.PubMedCrossRefGoogle Scholar
  16. 16.
    Alvarez F, Berg PA, Bianchi FP, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:928–937.CrossRefGoogle Scholar
  17. 17.
    Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.PubMedCrossRefGoogle Scholar
  18. 18.
    Kuiper EMM, Zondervan PE, Van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2010;8:530–534.PubMedCrossRefGoogle Scholar
  19. 19.
    EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.CrossRefGoogle Scholar
  20. 20.
    Al-Chalabi T, Portmann BC, Bernal W, Mcfarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008;28:209–220.PubMedCrossRefGoogle Scholar
  21. 21.
    Efe C, Purnak T, Ozaslan E. The diagnostic criteria for patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. Clin Gastroenterol Hepatol. 2010;8:734.PubMedCrossRefGoogle Scholar
  22. 22.
    Miyake Y, Iwasaki Y, Kobashi H, et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int. 2009;3:556–562.PubMedCrossRefGoogle Scholar
  23. 23.
    Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002;35:409–413.PubMedCrossRefGoogle Scholar
  24. 24.
    Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006;44:400–406.PubMedCrossRefGoogle Scholar
  25. 25.
    Czaja AJ. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J Hepatol. 2006;44:251–252.PubMedCrossRefGoogle Scholar
  26. 26.
    Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14:331–337.PubMedCrossRefGoogle Scholar
  27. 27.
    Olsson R, Glaumann H, Almer S, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med. 2009;20:190–196.PubMedCrossRefGoogle Scholar
  28. 28.
    Gheorghe L, Iacob S, Gheorghe C, et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol. 2004;16:585–592.PubMedCrossRefGoogle Scholar
  29. 29.
    Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms—IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33:1273–1291.PubMedCrossRefGoogle Scholar
  30. 30.
    Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J gastroenterol. 2010;16:934–947.PubMedCrossRefGoogle Scholar
  31. 31.
    Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol. 2008;14:3368–3373.PubMedCrossRefGoogle Scholar
  32. 32.
    Lüth S, Kanzler S, Frenzel C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Johnson PG, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology. 1993;18:998–1005.PubMedCrossRefGoogle Scholar
  34. 34.
    Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121:900–907.PubMedCrossRefGoogle Scholar
  35. 35.
    Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:901–910.PubMedCrossRefGoogle Scholar
  36. 36.
    Lindström L, Boberg KM, Wikman O, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther. 2012;35:451–457.PubMedCrossRefGoogle Scholar
  37. 37.
    Mieli-Vergani G, Heller S, Jara P, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2009;49:158–164.PubMedCrossRefGoogle Scholar
  38. 38.
    Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003;38:210–217.PubMedCrossRefGoogle Scholar
  39. 39.
    Malik TA, Gutierrez AM, McGuire B, et al. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome complicated by Crohn’s disease. Digestion. 2010;82:24–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Marilena Durazzo
    • 1
    Email author
  • Alberto Premoli
    • 2
  • Elena Paschetta
    • 1
  • Paola Belci
    • 1
  • Maurizio Spandre
    • 1
  • Simona Bo
    • 1
  1. 1.Department of Internal MedicineUniversity of TurinTurinItaly
  2. 2.Department of Internal MedicineS. Lazzaro HospitalAlbaItaly

Personalised recommendations